KEY TAKEAWAY: The American Medical Association today called for a ban on direct-to-consumer advertising of prescription drugs, with physicians suggesting that TV and magazine ads could be contributing to the rising cost of expensive treatments however, they are wrong and need to look at the facts.
Continue reading »
KEY IDEA: Shareholders vs. patients, who is more important? One pharma CEO is leaving no doubt that shareholders come first and has raised prices to appease the Street. Can CEO’s really balance patient needs with shareholder expectations? Continue reading »
KEY TAKEAWAY: The biggest threat to healthcare is NOT high drug prices but, rather obesity. Unless further government action is taken, the global obesity rate will rise another 4% by 2025, according to a new report from the World Obesity Federation. Continue reading »
KEY THOUGHT: Even if all prescription drugs were free health care costs would continue to climb because of unhealthy lifestyles. About half of American adults have either diabetes or prediabetes, a new study says and the cost of that alone could send healthcare costs into orbit. However, the media is too focused on the cost of prescription drugs. Continue reading »
KEY TAKEAWAY: Via the Finacial Times “Pharmaceutical companies must move towards new pricing models based on outcomes for patients if cash-strapped health systems are to remain solvent, according to the chief executive of Novartis.” Continue reading »
KEY TAKEAWAY: Drug prices, and big pharma, are going to be squarely in the crosshairs of big pharma in the next general election. He echoes the sentiments of a lot of the American Public and you can bet that insurers, as well as politicians, are going to do something about it to win votes. Continue reading »
KEY TAKEAWAY: The oncology drug pipeline is far larger than any other therapy area across the pharmaceutical industry, with 6,484 products in active development across all indications, but 90% of these drugs will not make it into Phase III clinical trials. Continue reading »
KEY TAKEAWAY: At $12.50 per patient a day, Entresto carries a substantially higher price tag than the older drugs, which cost less than a dollar a dose. However, Novartis is deploying digital tools to prove to insurers that their drug has better outcomes which, in turn, leads to lower long-term health care costs. Continue reading »
KEY TAKEAWAY: Via the NY Times “as complaints grow about exorbitant drug prices, pharmaceutical companies are coming under pressure to disclose the development costs and profits of those medicines and the rationale for charging what they do.” Continue reading »
KEY TAKEAWAY: Vertex, who is based in downtown Boston, got the kind of headlines that pharma has been trying to avoid. Three stories, talk about the high price of their new CF drug and the urges shareholders to reject compensation packages for senior executives.
Continue reading »
KEY TAKEAWAY: Biopharma can’t just read about high drug prices in media stories, employees need to get out and listen to patients talk about how it’s affecting their treatment choices and limiting the quality of life THEY want. Continue reading »